共轭聚合物高灵敏检测单核苷酸多态性助力高血压个体化治疗
研究采用阳离子共轭聚合物(CCP)介导的多步荧光共振能量转移(MS-FRET)技术检测高血压相关基因型。在150例住院高血压患者全血样本回顾性分析中成功识别10个基因座已知风险等位基因;随后在100例原发性高血压患者前瞻性临床试验中,基于MS-FRET结果个体化治疗较常规治疗提高血压控制率(94.0%对54.0%)并缩短达标时间(4.06±2.10天对5.82±1.84天)。
要点
- CCP-MS-FRET技术可定性检测中国人群高血压相关DNA基因型。
- 回顾性150例住院高血压患者全血样本中识别出10个基因座已知风险等位基因。
- 前瞻性100例原发性高血压患者中,基于MS-FRET的个体化治疗血压控制率94.0%对常规治疗54.0%。
核心结论
- 基于CCP的MS-FRET基因变异检测可能辅助临床医生快速准确地对高血压患者进行风险分类并改善治疗结局。
研究设计与样本
- 回顾性研究采用CCP-MS-FRET技术对150例住院高血压患者全血样本进行10个基因座的DNA基因型定性分析。
- 前瞻性临床试验纳入100例原发性高血压患者,比较基于MS-FRET结果的个体化治疗与常规治疗。
主要发现
- 回顾性研究150例住院高血压患者全血样本中,MS-FRET技术成功识别10个基因座的已知高血压风险等位基因。
- 前瞻性临床试验100例原发性高血压患者中,个体化治疗组血压控制率94.0% vs 常规治疗组54.0%。
- 前瞻性临床试验100例原发性高血压患者中,个体化治疗组血压达标时间4.06±2.10天 vs 常规治疗组5.82±1.84天。
临床怎么用
- 作者认为CCP-MS-FRET基因变异检测可能辅助临床医生快速准确地对高血压患者进行风险分类并改善治疗结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genetic variants among individuals have been associated with ineffective control of hypertension. Previous work has shown that hypertension has a polygenic nature, and interactions between these loci have been associated with variations in drug response. Rapid detection of multiple genetic loci with high sensitivity and specificity is needed for the effective implementation of personalized medicine for the treatment of hypertension. Here, we used a cationic conjugated polymer (CCP)-based multistep fluorescence resonance energy transfer (MS-FRET) technique to qualitatively analyze DNA genotypes associated with hypertension in the Chinese population. Assessment of 10 genetic loci using this technique successfully identified known hypertensive risk alleles in a retrospective study of whole-blood samples from 150 patients hospitalized with hypertension. We then applied our detection method in a prospective clinical trial of 100 patients with essential hypertension and found that personalized treatment of patients with hypertension based on results from the MS-FRET technique could effectively improve blood pressure control rate (94.0% versus 54.0%) and shorten the time duration to controlling blood pressure (4.06 ± 2.10 versus 5.82 ± 1.84 days) as compared with conventional treatment. These results suggest that CCP-based MS-FRET genetic variant detection may assist clinicians in rapid and accurate classification of risk in patients with hypertension and improve treatment outcomes.
引用
- Shen Q, Zhang H, Huang Y, et al. Sensitive detection of single-nucleotide polymorphisms by conjugated polymers for personalized treatment of hypertension. Sci Transl Med. 2023. PMID: 36888697. doi:10.1126/scitranslmed.abq5753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。